Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP783962.RAjpx2fQxJMNct4pTRj__xNZ8KAAgLbp2VAis0pViqtMQ130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP783962.RAjpx2fQxJMNct4pTRj__xNZ8KAAgLbp2VAis0pViqtMQ130_assertion type Assertion NP783962.RAjpx2fQxJMNct4pTRj__xNZ8KAAgLbp2VAis0pViqtMQ130_head.
- NP783962.RAjpx2fQxJMNct4pTRj__xNZ8KAAgLbp2VAis0pViqtMQ130_assertion description "[Experience with these agents in patients with refractory anemia with excess blasts in transformation (reclassified by the World Health Organization as AML) was also reported in the clinical trials submitted to the FDA for approval of azacitidine for MDS.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP783962.RAjpx2fQxJMNct4pTRj__xNZ8KAAgLbp2VAis0pViqtMQ130_provenance.
- NP783962.RAjpx2fQxJMNct4pTRj__xNZ8KAAgLbp2VAis0pViqtMQ130_assertion evidence source_evidence_literature NP783962.RAjpx2fQxJMNct4pTRj__xNZ8KAAgLbp2VAis0pViqtMQ130_provenance.
- NP783962.RAjpx2fQxJMNct4pTRj__xNZ8KAAgLbp2VAis0pViqtMQ130_assertion SIO_000772 16341239 NP783962.RAjpx2fQxJMNct4pTRj__xNZ8KAAgLbp2VAis0pViqtMQ130_provenance.
- NP783962.RAjpx2fQxJMNct4pTRj__xNZ8KAAgLbp2VAis0pViqtMQ130_assertion wasDerivedFrom befree-20140225 NP783962.RAjpx2fQxJMNct4pTRj__xNZ8KAAgLbp2VAis0pViqtMQ130_provenance.
- NP783962.RAjpx2fQxJMNct4pTRj__xNZ8KAAgLbp2VAis0pViqtMQ130_assertion wasGeneratedBy ECO_0000203 NP783962.RAjpx2fQxJMNct4pTRj__xNZ8KAAgLbp2VAis0pViqtMQ130_provenance.